rlanzara Bio Balance, Inc. Mr Dr/Pharmacology Richard/LanzaraScientific-Research




  • Name:

    Dr/Pharmacology Richard/Lanzara

  • Institution:

    Bio Balance, Inc.

  • Position:

    President & Principal Scientific Officer Bio Balance, Inc.

  • Location:

    New York United States

  • Field of Science:

    Scientific-Research

  • Website / Blog:

    www.bio-balance.com/

  • Online Status: status







    		•

    • About my Work: 


      My research areas include the following:

      1) A general biophysical model for GPCR activation that provides a molecular description that addresses many disparate experimental observations including pH-dependence, redox sensitivity, thiol sensitivity and allosteric modulation (L. Rubenstein, R. Lanzara, Activation of G Protein-coupled receptors entails cysteine modulation of agonist binding, J. Mol. Struct. (THEOCHEM) 430 (1998) 57–71 and L.A. Rubenstein, R.J. Zauhar, R.G. Lanzara, Molecular dynamics of a biophysical model for beta-2-adrenergic and G protein-coupled receptor activation Journal of Molecular Graphics and Modelling 25 (2006) 396-409).

      2) A mathematical model of receptor activation that also produces a model for rapid desensitization (Lanzara, R. Optimal Agonist/Antagonist Combinations Maintain Receptor Response by Preventing Rapid Beta-1 adrenergic Receptor Desensitization Intl. J. Pharmacol., 1(2): 122-131, (2005)).

      3) A method to reduce or prevent rapid receptor desensitization (R. Lanzara, Method for Determining Drug Compositions to Prevent Desensitization of Cellular Receptors, U.S. Patent #5,597,699 (1997) and R. Lanzara, Compositions to Enhance the Efficacy and Safety of Biopharmaceutical Drugs. U.S. Patent #6,593,094 (2003)).

      4) A physical model for Weber’s law that describes a fundamental equation for equilibrium, which can be usefully applied to describe biological systems (Lanzara, R.G. Weber's Law Modeled by the Mathematical Description of a Beam Balance, Mathematical Biosciences 122: 89-94 (1994)).

    • Projects: 


    • Vita / Publications: 


      SELECTIVE SCIENTIFIC PUBLICATIONS:

      1. Rubenstein, L.A., Zauhar, R.J., Lanzara, R.G. Molecular dynamics of a biophysical model for beta-2-adrenergic and G protein-coupled receptor activation Journal of Molecular Graphics and Modelling 25: 396-409 (2006).
      2. Lanzara, R. Optimal Agonist/Antagonist Combinations Maintain Receptor Response by Preventing Rapid Beta-1-adrenergic Receptor Desensitization, International Journal of Pharmacology 1(2): 122-131 (2005).
      3. Rubenstein, L.A. and Lanzara, R.G. Activation of G Protein-Coupled Receptors Entails Cysteine Modulation of Agonist Binding, J. Molecular Structure (Theochem) 430/1-3: 57-71 (1998).
      4. Lanzara, R.G. Weber's Law Modeled by the Mathematical Description of a Beam Balance, Mathematical Biosciences 122: 89-94 (1994).
      5. Lanzara, R.G. A Novel Biophysical Model for Receptor Response, Canadian Journal of Physiology and Pharmacology 72: 559 (1994).
      6. Lanzara, R., Liebman, M. & Wilk, S. The Use of Analogues of TRH to Probe the Specificity of Pyroglutamyl Peptidase II. In Thyrotropin-Releasing Hormone; Annals of the New York Academy of Sciences, G. Metcalf & I. Jackson, Eds., The N. Y. Acad. Sci. 553: 559-562 (1989).
      7. Kirchberger, M.A., Borchman, D., Kasinathan, C. & Lanzara, R.G. Proteolytic Activation of the Calcium Pump of Canine Cardiac Sarcoplasmic Reticulum. Biophysical Journal 49: 236a (1986).

      PATENTS:
      1. Lanzara, R.G. Drug composition to prevent desensitization of cellular receptors. U. S. Pat. 6,673,558 (2004).
      2. Lanzara, R.G. Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs. U. S. Pat. 6,593,094 (2003).
      3. Lanzara, R.G. A Method for determining drug compositions to prevent desensitization of cellular receptors. U. S. Pat. 5,597,699 (1997).

      SCIENTIFIC PRESENTATIONS:
      1. Poster Presentation: A Novel Biophysical Model for Receptor Response, the XIIth International Congress of Pharmacology, 24-29 July 1994, Montreal, Canada.
      2. Poster Presentation: A Novel Biophysical Model for Receptor Response, the New York Academy of Sciences Conference: Receptor Activation by Antigens, Cytokines, Hormones and Growth Factors, October 21-25 1994, Orlando, Florida.

      (see - http://www.bio-balance.com/Ref.htm )
      		•

    • Grants and Awards: 


    • About my Institution: 


      BIO BALANCE INC., a New York corporation, founded in 1993, is engaged in studies of biomedical problems.

      The philosophy behind Bio Balance is that accurate descriptions of drug-receptor interactions will lead to the development of better pharmaceuticals. Bio Balance is devoted to a biophysical description of the initial receptor response. This should lead to improved pharmaceuticals and be an attractive and alternative route to drug development in the future.

    • Additional Information: 


      		•

     

































     

    Powered free by PHPmotion